Trial reportLung cancer (Amsterdam, Netherlands)2010
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.
Trial report in Lung cancer (Amsterdam, Netherlands), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06262386 (Utilizing Perioperative Variation Trends of Circulating Tumor Cells and Tumor Pathological Characteristics as a Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial), which is not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Utilizing Perioperative Variation Trends of Circulating Tumor Cells and Tumor Pathological Characteristics as a Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.The oncologist · 2014Pooled it
- The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.European journal of cancer (Oxford, England : 1990) · 2019Trial
- SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016Trial
- Trial
- Trial
- VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.British journal of cancer · 2012Trial
- Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2012Trial
- Semi-Quantitative MALDI Measurements of Blood-Based Samples for Molecular Diagnostics.Molecules (Basel, Switzerland) · 2022Article
- Circulating Tumor Cells as a Tool of Minimal Residual Disease Can Predict Lung Cancer Recurrence: A longitudinal, Prospective Trial.Diagnostics (Basel, Switzerland) · 2020Article
- The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.BMC cancer · 2018Article
- Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.Journal of proteome research · 2018Article
- Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.British journal of cancer · 2017Observational
- Article
- Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer.Anticancer research · 2016Article
- Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer.Journal of hematology & oncology · 2015Review
- The value of proteomics in lung cancer.Annals of translational medicine · 2015Article
- Molecular pathways and therapeutic targets in lung cancer.Oncotarget · 2014Review
- Proteomic biomarkers in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2013Review
- QiShenYiQi Pills, a Compound Chinese Medicine, Ameliorates Doxorubicin-Induced Myocardial Structure Damage and Cardiac Dysfunction in Rats.Evidence-based complementary and alternative medicine : eCAM · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.